Effect of AD-5423 on animal models of schizophrenia: Phencyclidine-induced behavioral changes in mice

NeuroReport

Volumn 14, Issue 2, 2003, Pages 269-272

  Nagai, T ^a   Noda, Y ^a   Une, T ^b   Furukawa, K ^b   Furukawa, H ^c   Kan, Q M ^a   Nabeshima, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

AD 5423 (blonanserin); Animal model; Phencyclidine (PCP); Schizophrenia; Serotonin dopamine antagonist

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; BLONANSERIN; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; PHENCYCLIDINE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; HYPERACTIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SWIMMING; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; IMMOBILIZATION; MALE; MICE; MOTOR ACTIVITY; PHENCYCLIDINE; PIPERAZINES; PIPERIDINES; SCHIZOPHRENIA;

EID: 0037428772     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200302100-00023     Document Type: Article

References (24)

1. Crow TJ. Br Med J 12, 66-68 (1980).
2. Oka M, Noda Y, Ochi Y et al. J Pharmacol Exp Ther 264, 158-165 (1993).
3. Noda Y, Kurumiya S, Miura Y et al. J Pharmacol Exp Ther 265, 745-751 (1993).
4. Hurlbut KM. Emerg Med Clin North Am 9, 31-52 (1991).
5. Javitt DC and Zukin SR. Am J Psychiatry 148, 1301-1308 (1991).
6. Volkow ND and Fowler JS. Semin Nucl Med 22, 254-267 (1992).
7. Noda Y, Yamada K, Komori Y et al. Br J Pharmacol 117, 1579-1585 (1996).
8. Kitaichi K, Yamada K, Yoneda Y et al. Life Sci 56, 531-543 (1995).
9. Noda Y, Yamada K, Furukawa H et al. Br J Pharmacol 116, 2531-2537 (1995).
10. Noda Y, Mamiya T, Furukawa H et al. Eur J Pharmacol 324, 135-140 (1997).
11. Noda Y, Kamei H, Mamiya T et al. Neuropsychopharmacology 23, 375-387 (2000).
12. Corbett R, Zhou L, Sorensen SM et al. Neuropsychopharmacology 21, 211-218 (1999).
13. Guan HJ, Dai J and Zhu XZ. Acta Pharmacol Sin 21, 205-210 (2000).
14. Maddox VH, Godefroi EF and Parcell RF. J Med Chem 8, 230 (1965).
15. Oades RD, Rao ML, Bender S et al. Behav Pharmacol 11, 317-330 (2000).
16. Hirschowitz J, Hitzemann R, Burr G et al. Neuropsychopharmacology 5, 103-113 (1991).
17. Chouinard G, Jones B, Remington G et al. J Clin Psychopharmacol 13, 24-45 (1993).
18. Reynolds GP. Trends Pharmacol Sci 13, 116-121 (1992).
19. Boyer P, Lecrubier Y and Puech AJ. Mod Probl Pharmacopsychiatry 24, 152-174 (1990).
20. Levinson DF. Clin Ther, 326-352 (1991).
21. Gelders YG, Ceulemans DLS, Reyntjens A et al. The influence of selective serotonin antagonism on conventional neuroleptic therapy. In: Proceedings of the four world congress of biological psychiatry. 1985, p. 417.
22. Gelenberg AJ and Doller JC. J Clin Psychiatry 40, 238-240 (1979).
23. Castelao JF, Ferreira L, Gelders YG et al. Schizophr Res 2, 411-415 (1989).
24. Lieberman JA, Kane JM and Johns CA. J Clin Psychiatry 50, 329-338 (1989).